- Home
- VBIO vs HLSQ Comparison
VBIO vs HLSQ Comparison
Compare VBIO & HLSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VBIO | HLSQ |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 972.0K |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VBIO | HLSQ |
|---|---|---|
| Price | $0.93 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 658.1K | ★ 964.7K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 560.42 |
| EPS | N/A | ★ 3.56 |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $0.20 |
| 52 Week High | $812.50 | $0.77 |
Technical Indicators
Market Signals| Indicator | VBIO | HLSQ |
|---|---|---|
| Relative Strength Index (RSI) | 22.30 | 23.73 |
| Support Level | $0.12 | $0.20 |
| Resistance Level | $4.39 | $0.45 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 1.97 | 0.01 |
| Stochastic Oscillator | 1.29 | 33.17 |
Price Performance
Historical ComparisonAbout VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
About HLSQ Tessera Defense and Homeland Security Inc. Common Stock
Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.